MDT.N Hits 52-Week High on Strong Q2 Results
Shares of Medtronic plc (MDT.N) surged to a 52-week high following the company's impressive Q2 FY26 earnings report, which revealed a revenue increase of 6.6% to $9.0 billion and a GAAP diluted EPS rise of 8% to $1.07, surpassing analyst expectations. The stock's breakout was fueled by robust performance in the Cardiac Ablation Solutions segment, which saw a remarkable 71% revenue growth, particularly driven by the pulsed field ablation portfolio. Additionally, Medtronic raised its FY26 revenue growth guidance to approximately 5.5%, reflecting strong confidence in ongoing growth and market expansion, particularly with new product approvals enhancing its portfolio. Despite the positive outlook, some analysts express concerns over potential overvaluation in the current market.
Trade with 70% Backtested Accuracy
Analyst Views on MDT
About MDT
About the author

- Strong Market Performance: The S&P 500 index rose 9.6% in the first half of 2026, achieving nearly a 15% increase in the second quarter, marking its best quarterly performance since 2020, despite investors facing turbulence including the onset of the Iran war.
- Low Volatility Stock Recommendations: UBS highlights the lagging performance of low volatility stocks as capital has concentrated in AI-driven sectors, suggesting investors focus on high-quality companies with resilient fundamentals and attractive valuations to mitigate portfolio swings.
- Positive Outlook for Yum Brands: The parent company of Taco Bell and KFC, Yum Brands, is expected to achieve its highest cash flow return on investment by 2027, with plans for international expansion and a KFC loyalty program driving topline growth, and its stock has risen over 10% this year.
- Significant Potential for Lockheed Martin: While UBS maintains a neutral stance on Lockheed Martin, it anticipates a positive reaction to its upcoming second-quarter earnings report, with a $35 billion defense contract potentially boosting 2026 performance, and the stock has increased by about 10%.
- AbbVie's Stability: AbbVie has increased its dividend for 50 consecutive years, currently offering a 2.65% yield, with analysts projecting a 12%-13% average annual earnings growth over the next three years, showcasing its robust ability to refresh its drug portfolio and compete in the market.
- Medtronic's Growth Potential: Medtronic has raised its dividend for 49 years, with a current yield of 3.43%, and is expected to achieve 5%-6% annualized earnings growth, while its newly launched Hugo system may provide additional growth in the robotics-assisted surgery sector.
- Bristol Myers Squibb's Risks and Opportunities: Bristol Myers Squibb offers a 4.3% dividend yield but faces risks from patent expirations that could impact revenue; however, its development pipeline aims to introduce 10 new drugs in the coming years, presenting growth potential.
- Industry Outlook Analysis: The healthcare sector is projected to reach $5.7 trillion in spending by 2025, and while high-yield stocks carry risks, the stable market demand and innovation in pharmaceuticals make long-term investments appealing.
- Da Vinci System Innovation: Intuitive Surgical's Da Vinci 5 system installations reached 232 in Q1, a 58% increase from 147 a year earlier, demonstrating strong market momentum for the new product and further solidifying the company's market leadership.
- Strong Competitive Moat: With most surgeons trained on the Da Vinci system, hospitals tend to stick with the platform after purchase, significantly reducing the threat from competitors and ensuring Intuitive Surgical's sustained profitability.
- Diverse Revenue Streams: In the latest quarter, revenue from accessories and instruments totaled $1.6 billion, compared to $650 million from system sales, indicating the company's ability to generate high recurring revenue through accessories and service contracts, enhancing financial stability.
- Global Market Expansion: The installed base of Da Vinci systems grew to 11,395, a 12% year-over-year increase, while global procedures rose by 16%, indicating increased hospital reliance on the platform, thereby driving long-term revenue growth for the company.
- Market Leadership: Intuitive Surgical's Da Vinci surgical robot maintains a dominant position in operating rooms globally, with 232 placements of the Da Vinci 5 system in Q1, reflecting a 58% year-over-year increase, which reinforces the company's market position.
- Strong Competitive Moat: Most surgeons trained on the Da Vinci system tend to prefer it, and hospitals are likely to continue using it after making a significant investment, reducing competitive threats and positively impacting the company's earnings outlook.
- Diverse Revenue Streams: In the latest quarter, revenue from accessories and instruments reached $1.6 billion, significantly exceeding the $650 million from system sales, indicating that the company has established a sustainable recurring revenue model that enhances financial stability.
- Expanding Market Share: The installed base of Da Vinci systems has grown to 11,395, a 12% year-over-year increase, with a 16% rise in procedures, indicating increased hospital reliance on the platform and laying a solid foundation for future revenue growth.
- Medical Device Leader: Medtronic boasts a 49-year dividend growth history with a current yield of 3.5%, and despite market fluctuations, its latest report indicates the highest annual revenue growth in a decade, reflecting effective restructuring efforts to enhance profitability.
- Real Estate Investment Trust: Realty Income offers a 5.2% dividend yield and has increased dividends for 31 consecutive years; as the largest net lease REIT, its portfolio spans North America and Europe, maintaining over 96% occupancy during economic downturns, showcasing its stability and reliability.
- Steel Industry Leader: Nucor, recognized as a Dividend King with over 50 consecutive annual hikes, currently has a low yield of 0.9%, yet its modern electric arc steel mills and strong employee relations enable it to perform well amid cyclical fluctuations, making it a solid long-term hold.
- Long-Term Investment Strategy: The author emphasizes a commitment to holding these quality stocks through market volatility, believing that Medtronic, Realty Income, and Nucor are proven successful companies that will continue to grow, making them worthy of attention for long-term investors.
- Healthcare Giant: Medtronic has maintained a dividend increase streak for 49 years, with a current yield of 3.5%, and despite market downturns, it recently reported its highest annual revenue growth in a decade, indicating a successful restructuring and potential for stable dividend growth even in a bear market.
- Real Estate Investment Trust: Realty Income offers a 5.2% dividend yield and has increased its dividend for 31 consecutive years; while not at historical highs, its absolute yield remains attractive, and its occupancy rate never dropped below 96% during the Great Recession, showcasing its reliability amid market fluctuations.
- Steel Industry Leader: Nucor, known for over 50 consecutive years of dividend increases, currently has a low yield of 0.9%, but has only reported one loss in the last four decades, demonstrating resilience in a cyclical industry, making it a potential quality pick for investors during a bear market.
- Long-Term Holding Strategy: The author intends to hold Medtronic, Realty Income, and Nucor through market volatility, believing that these companies' management capabilities and historical performance will enable continued growth in future market conditions, reflecting the value of long-term investing.











